1. Home
  2. Topics
  3. Change of Program Name from APA to P-CAB

Topics

Change of Program Name from APA to P-CAB

RaQualia today announced that the Company indicated to change its program name “Acid Pump Antagonist (APA)”, one of the Company's core program, to “Potassium-Competitive Acid Blocker (P-CAB)”.

 

APA and P-CAB are the different terms which indicate the same drug mechanism of action. The decision was made based on the higher public recognition of P-CAB than that of APA of recent date.

 

CJ HealthCare Corporation (CJ), the licensee of tegoprazan (also known as RQ-00000004/CJ-12420), is currently conducting Phase III clinical trials in Korea. RaQualia completed Phase I clinical trials of tegoprazan in the US and in Japan.

 

RaQualia intend to support CJ continuously to complete Korean New Drug Application (NDA) of tegoprazan successfully as well as to facilitate global licensing activities.

 

####

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics